SCHEMBL19577795

SCHEMBL19577795

B[C@@H]1O[C@H](COCB[C@@H]2O[C@H](COC)C(OP(C)(=S)S)C2F)C(OP(C)(=S)S)C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19577791 0.85 — —
SCHEMBL21202643 0.82 — —
SCHEMBL19577796 0.78 — —
SCHEMBL21202662 0.78 — —
SCHEMBL19577792 0.78 — —
SCHEMBL24742684 0.72 — —
SCHEMBL17754509 0.71 — —
SCHEMBL21202645 0.70 SMPD1 (0.30) —
SCHEMBL21474777 0.70 SMPD1 (0.30) —
SCHEMBL21202664 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11213541-B2 Antisense-oligonucleotides as inhibitors of TGF-R signaling Neurovision Pharma GmbH (DE) 2022-01-04 — — US disclosed
US-20170319614-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2017-11-09 — — US disclosed
Send feedback